SOHO Brazil 2022

https://rvmais.iweventos.com.br/site/sintoma2022

 

SOHO Brazil 2022
Avatar

SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-Up” the Class

By SOHO Brazil 2022 FEATURING Nitin Jain, Phillip Scheinberg
By SOHO Brazil 2022 FEATURING Nitin Jain, Phillip Scheinberg
23 views
August 30, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
Leukemia
23:10

SOHO Brazil 2022: All You Need to Know (Until Now) About Targeted Th…

SOHO Brazil 2022

K. Pratz, P. Scheinberg

86 views
32:48

SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indi…

SOHO Brazil 2022

M. Bishop, P. Scheinberg

12 views
16:45

SOHO Brazil 2022 on CLL: The PI3K Inhibitors, the "Not-So-New Kid on…

SOHO Brazil 2022

N. Jain, P. Scheinberg

14 views
20:09

SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-U…

SOHO Brazil 2022

N. Jain, P. Scheinberg

23 views
22:54

SOHO Brazil 2022 on Ph+ ALL: Is the Combination With TKIs Curing Pat…

SOHO Brazil 2022

J. Ribera, P. Scheinberg

47 views
20:04

SOHO Brazil 2022 on High-Risk AML: Is Conventional Chemo Still the B…

SOHO Brazil 2022

D. Pollyea, P. Scheinberg

16 views
20:23

SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: What…

SOHO Brazil 2022

D. Pollyea, P. Scheinberg

17 views
26:48

SOHO Brazil 2022 on CLL: Do BTKi + BCL2 Inhibitors Need a Partner?

SOHO Brazil 2022

N. Jain, P. Scheinberg

16 views
25:29

SOHO Brazil 2022: Can Someone Be Destined to Develop AML? Understand…

SOHO Brazil 2022

L. Godley, P. Scheinberg

32 views